| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/J.AJKD.2003.12.023 |
| P698 | PubMed publication ID | 15042535 |
| P50 | author | Vasilios G. Athyros | Q37837494 |
| Dimitri P Mikhailidis | Q62561943 | ||
| P2093 | author name string | Moses Elisaf | |
| Athanasios A Papageorgiou | |||
| Athanasios N Symeonidis | |||
| GREACE Study Collaborative Group | |||
| Anthimos N Pehlivanidis | |||
| Haralambos J Milionis | |||
| Vasilios I Bouloukos | |||
| P433 | issue | 4 | |
| P921 | main subject | patient | Q181600 |
| dyslipidemia | Q66291209 | ||
| heart disease | Q190805 | ||
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 589-599 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | American Journal of Kidney Diseases | Q4744250 |
| P1476 | title | Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study | |
| P478 | volume | 43 |
| Q34029759 | A Metabonomics Profiling Study on Phlegm Syndrome and Blood-Stasis Syndrome in Coronary Heart Disease Patients Using Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry |
| Q34473275 | A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults |
| Q36829002 | Analysis of antihypertensive effects of statins. |
| Q92218986 | Antiplatelet and Lipid-lowering Drugs in Hypertension |
| Q51110244 | Association of glomerular filtration rate with slow coronary flow in patients with normal to mildly impaired renal function. |
| Q33971640 | Associations of non-high density lipoprotein cholesterol and traditional blood lipid profiles with hyperuricemia among middle-aged and elderly Chinese people: a community-based cross-sectional study |
| Q45238669 | Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients |
| Q37138777 | Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure? |
| Q26997059 | Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update |
| Q86368122 | Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan |
| Q92336234 | Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects |
| Q51365171 | Determinants of blood uric acid levels in a dyslipidemic Arab population. |
| Q28192856 | Diagnosis and management of the metabolic syndrome in obesity |
| Q28222549 | Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? |
| Q36364965 | Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences |
| Q46514296 | Effect of apolipoprotein E polymorphism on serum uric acid levels in healthy subjects. |
| Q44960569 | Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease |
| Q30054768 | Effects of Three Strong Statins (Atorvastatin, Pitavastatin, and Rosuvastatin) on Serum Uric Acid Levels in Dyslipidemic Patients |
| Q46803015 | Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension |
| Q44973053 | Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial |
| Q28220294 | Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review |
| Q36769535 | Gender-related differences in the association between serum uric acid and left ventricular mass index in patients with obstructive hypertrophic cardiomyopathy |
| Q42756654 | Hyperuricaemia in cardiovascular diseases: a passive or an active player? |
| Q35691372 | IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis |
| Q38853504 | Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis |
| Q39033643 | Impact of allopurinol on risk of myocardial infarction |
| Q36365884 | Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial |
| Q38241233 | Improving cardiovascular and renal outcomes in gout: what should we target? |
| Q35219367 | Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus |
| Q37245464 | Kidney function and estimated vascular risk in patients with primary dyslipidemia |
| Q36081593 | Matrix metalloproteinases and diabetic vascular complications. |
| Q28256994 | New developments in clinically relevant mechanisms and treatment of hyperuricemia |
| Q36653658 | Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview |
| Q41205100 | Off target effects of statins shape total mortality? |
| Q83382795 | Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study |
| Q37142044 | Pleiotropic effects of thiazolidinediones |
| Q51034935 | Prevalence of metabolic syndrome according to different definitions in a hypertensive population. |
| Q35952447 | Prevention and treatment of the metabolic syndrome. |
| Q79840777 | Prognostic significance of serum uric acid in acute myocardial infarction |
| Q35819589 | Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome |
| Q46486524 | Risk modification in patients with peripheral arterial disease: a retrospective survey |
| Q36557850 | Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance |
| Q42791977 | Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis |
| Q36271814 | Secondary prevention of ischemic cerebrovascular disease. What is the evidence? |
| Q89604917 | Serum Uric Acid Levels and Risk of Intracranial Atherosclerotic Stenosis: A Cross-Sectional Study |
| Q51309856 | Serum Uric Acid, Gender, and Low Ankle Brachial Index in Adults With High Cardiovascular Risk. |
| Q35225010 | Serum uric acid and cardiovascular disease. |
| Q36540330 | Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived |
| Q46459227 | Serum uric acid concentration and asymptomatic hyperuricemia with subclinical organ damage in general population. |
| Q48722227 | Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. |
| Q45111248 | Serum uric acid levels are associated with atrial fibrillation in patients with ischemic heart failure |
| Q46917502 | Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease |
| Q36908540 | Should a statin be prescribed to every patient with heart failure? |
| Q46727401 | Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering? |
| Q35232279 | Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel |
| Q82379275 | Statin use in patients with chronic kidney disease stages 2-4: targeting beyond improved mortality rates |
| Q36944127 | Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients |
| Q36984049 | Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study |
| Q26998966 | Statins in heart failure: do we need another trial? |
| Q36411099 | Statins: another class of antihypertensive agents? |
| Q26774109 | Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q51372447 | The influence of risk factors for metabolic syndrome on vascular complications. |
| Q21342788 | The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease |
| Q92218833 | Uric Acid and Cardiovascular Disease: An Update |
| Q79689991 | Uric acid and cardiovascular risk |
| Q45389592 | Uric acid and coronary collateral circulation: to be or not to be? |
| Q24678615 | Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? |
| Q37738006 | Uric acid as a factor in the metabolic syndrome. |
| Q37958283 | Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis |
Search more.